13 May 2024
You are about to leave the Clinical Value website now.
Cancel
Continue
Cervical Cancer
No woman left behind: Increasing access to testing for cervical cancer elimination
Read ArticleNo woman left behind: Increasing access to testing for cervical…
Cervical cancer has a high disease burden in APAC, with 50% of global cases and 60% of global deaths occurring in APAC. Almost all (99%) cervical cancer cases are linked to infection with high risk human papillomavirus, which is easily preventable through vaccination, advances in screening, and appropriate treatment. However, barriers still exist that prevent some women from being screened for cervical cancer
Expert Opinions
13 May 2024
Advancing women’s health: Project Teal drives cervical cancer screening in Hong Kong
Key Publications
13 May 2024
Impact and opportunity: the case for investing in women’s cancers in Asia Pacific
13 May 2024
WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention
13 May 2024
Recommendations for Use of p16/Ki67 Dual Stain for Management of Individuals Testing Positive for Human Papillomavirus
Webinars and Symposiums
Empowering Women Through Self-Sampling Towards the Elimination of Cervical Cancer
Future of incorporating HPV self-sampling into Singapore Guideline? Are we ready?
Overview of the Current Cervical Cancer Screening Landscape in Singapore
21st International Congress of Cytology – HPV Primary Screening with Biomarker Based Triage: A better cervical cancer screening strategy
IPVC 2023 – How Peru broke down barriers to cervical cancer screening
IPVC 2023 – Optimising screening and triage for cervical cancer: Prof Mark Stoler on why biomarkers are best
AOGIN 2022 – Advancing women’s health: optimising cervical cancer screening in Thailand
AOGIN 2022 – Advancing women’s health: HPV screening methods in Singapore
Disease Awareness
13 May 2024
Cervical cancer survivor shares journey from diagnosis to recovery
